Shanghai Junshi Biosciences (HKG:1877) completed the sale of 41 million H shares in a transaction valued at around HK$1.04 billion, according to a Friday bourse filing.
Shares gained about 7% in Monday's afternoon trade.
The cancer medicine developer sold the shares at HK$25.35 apiece and proceed raised will be used to advance the development of its therapies, it said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。